基于阿仑单抗的减低强度预处理用于X连锁凋亡抑制蛋白缺乏症。 - Suppr | 超能文献

Alemtuzumab-based reduced-intensity conditioning for XIAP deficiency.

作者信息

Kobushi Hirokazu, Umeda Katsutsugu, Hiejima Eitaro, Kato Kentaro, Sugimoto Mayumi, Kanegane Hirokazu, Takita Junko

机构信息

Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Department of Pediatrics, Graduate School of Medical Sciences, Tokushima University, Kyoto, Japan.

出版信息

Pediatr Int. 2023 Jan-Dec;65(1):e15576. doi: 10.1111/ped.15576.

DOI:10.1111/ped.15576

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Alemtuzumab-based reduced-intensity conditioning for XIAP deficiency.基于阿仑单抗的减低强度预处理用于X连锁凋亡抑制蛋白缺乏症。

Pediatr Int. 2023 Jan-Dec;65(1):e15576. doi: 10.1111/ped.15576.

2

Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.减低强度预处理造血细胞移植是治疗与信号淋巴细胞激活分子相关蛋白缺陷/1型X连锁淋巴增殖性疾病患者的有效方法。

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003. Epub 2014 Jun 9.

3

Haploidentical Hematopoietic Stem Cell Transplantation for XIAP Deficiency: a Single-Center Report.XIAP 缺陷的单倍体造血干细胞移植：单中心报告。

J Clin Immunol. 2020 Aug;40(6):893-900. doi: 10.1007/s10875-020-00795-6. Epub 2020 Jul 5.

4

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.阿仑单抗中等剂量方案可降低噬血细胞性淋巴组织细胞增生症患者接受降低强度预处理的造血干细胞移植后混合嵌合体的发生率。

Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10.

5

Successful Allogeneic Hematopoietic Stem Cell Transplantation in XIAP Deficiency Using Reduced-Intensity Conditioning.采用减低剂量预处理成功进行X连锁凋亡抑制蛋白缺陷患者的异基因造血干细胞移植

Pediatr Blood Cancer. 2016 Feb;63(2):355-7. doi: 10.1002/pbc.25756. Epub 2015 Sep 23.

6

Reduced-Intensity/Reduced-Toxicity Conditioning Approaches Are Tolerated in XIAP Deficiency but Patients Fare Poorly with Acute GVHD.XIAP 缺陷患者可耐受减强度/减毒性调理方法，但急性移植物抗宿主病的患者预后不良。

J Clin Immunol. 2022 Jan;42(1):36-45. doi: 10.1007/s10875-021-01103-6. Epub 2021 Sep 29.

7

Complications of Reduced Intensity Conditioning HSCT for XIAP Deficiency (Alloimmune Cytopenias and HLH) Successfully Managed With Donor Lymphocyte Infusion.低强度预处理造血干细胞移植治疗 XIAP 缺陷（同种免疫性血细胞减少症和噬血细胞性淋巴组织细胞增生症）的并发症通过供体淋巴细胞输注成功处理。

J Pediatr Hematol Oncol. 2015 Apr;37(3):e198-9. doi: 10.1097/MPH.0000000000000191.

8

Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation.基于阿仑单抗的低强度异基因造血干细胞移植中，3个月时的混合T细胞嵌合状态随后进行供体淋巴细胞输注与良好预后独立相关。

Leuk Lymphoma. 2020 Jan;61(1):202-205. doi: 10.1080/10428194.2019.1650177. Epub 2019 Aug 11.

9

Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis.采用基于抗体的预处理方案成功进行干细胞移植治疗伴有难治性噬血细胞性淋巴组织细胞增生症的XIAP缺陷症。

Blood. 2013 Jun 13;121(24):4966-8. doi: 10.1182/blood-2013-01-478735.

10

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.XIAP 缺陷的异基因造血细胞移植：国际调查显示预后不良。

Blood. 2013 Feb 7;121(6):877-83. doi: 10.1182/blood-2012-06-432500. Epub 2012 Nov 6.

引用本文的文献

1

Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity.异体造血细胞移植使用阿仑单抗治疗亚洲免疫性先天缺陷患者。

J Clin Immunol. 2024 May 22;44(6):126. doi: 10.1007/s10875-024-01734-5.